Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroMETa-CRC-064: ABBV-400 vs Lonsurf plus bevacizumab in refractory metastatic colorectal cancer
2024-512804-20-00Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of telisotuzumab adizutecan in colorectal cancer (CRC) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Stage 1: Percentage of participants with adverse events, Stage 1: Percentage of participants with potentially clinically significant vital sign measurements and 4 more. Started Dec 2025; status: completed.
02
Drugs
telisotuzumab adizutecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-512804-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512804-20-00.